Teladoc Health, Inc. Stock Performance and Valuation Insight
InvestingPro’s Fair Value analysis, released on 11 February 2026, identified Teladoc Health, Inc. (NYSE:TDOC) as significantly undervalued when the share price was $4.68. The model calculated an intrinsic value of $7.15, implying a 52.78 % upside potential. By early June 2026 the stock had rallied to $7.34, delivering a total return of 69 %—exceeding the original upside estimate. Monthly price gains were 11 % in April 2026 and 26 % in May 2026, following a 22 % decline in January 2026.
The Fair Value methodology aggregates discounted cash‑flow models, comparable‑company analyses, dividend‑discount models and analyst consensus targets, applying a margin‑of‑safety filter and forward cash‑flow projections to derive the intrinsic worth. An updated February analysis now places the intrinsic value at $10.97, suggesting the stock remains 44 % below its calculated fair value.
Operational and Financial Highlights
- Teladoc serves approximately 93 million subscription members across more than 450 medical subspecialties.
- Reported revenue for the most recent period was $2.53 billion.
- Gross margin stood at 70.82 %, indicating strong unit economics.
- Earnings per share improved from –$1.14 to –$0.96, narrowing the loss.
- EBITDA increased from $33 million to $47.5 million, reflecting better profitability.
Strategic Developments
The company announced a significant partnership with Walmart to integrate virtual care services into the retailer’s platform, a development cited as a catalyst for the stock’s upside.
Market Reaction
Following the earnings beat and partnership news, multiple analysts upgraded Teladoc, including Deutsche Bank and Bank of America, reinforcing the valuation thesis highlighted by InvestingPro.
Outlook
InvestingPro’s current Fair Value estimate of $10.97 suggests an additional 44 % upside from the early‑June price level, encouraging investors who accessed the February analysis to have realized substantial gains.